PAC-1
- Generic Name
- PAC-1
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28N4O2
- CAS Number
- 315183-21-2
- Unique Ingredient Identifier
- 9LIS8N0B2C
- Background
PAC-1 has been used in trials studying the treatment of Lymphoma, Melanoma, Solid Tumors, Breast Cancer, and Thoracic Cancers, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Arkadiusz Z. Dudek, MD
- Target Recruit Count
- 6
- Registration Number
- NCT04589832
- Locations
- 🇺🇸
HealthPartners Institute Regions Cancer Care Center, Minneapolis, Minnesota, United States
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Vanquish Oncology, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02355535
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Regions Hospital, Saint Paul, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath